Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201706-06 Lead optimization of anti-cancer RNA oligonucleotide inducing immunogenic tumor death(Oncology, Genetics) [2019-03-18]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of RNA-based anti-cancer drug that induces immunogenic apoptosis of a tumor by targeting retinoic acid-inducible gene I (RIG-I)

Unmet Medical Need & Target Patients

- Patients with cancers that can be treated by intratumoral injections. However, the indications can be expanded with further development on the targeted RNA delivery system.

- Current immunotherapy of cancer suffers from low response rates possibly due to heterogenetic nature of tumors. There is a growing list of pipelines that exploit novel mechanisms to activate tumor-targeted immunity.

Status

- Completed preliminary in vitro / in vivo efficacy test.

- Completed preliminary MOA of novel RIG-I agonist.

- Developed a platform to design the novel RIG-I agonists

Intellectual Property

Total 12 non-provisional patent applications in Korea, PCT, USA, and Europe.

Competitive Advantages

-    A novel pattern recognition molecular pattern (PAMP) for RIG-I that has not been reported elsewhere. 
-    Flexible chemical modifications lower the technical barriers in the development process of anti-cancer drugs.  

Contact & Company Overview

  • Company Name :
    KAIST
  • Homepage :
  • Contact Person :
    ByongSeok Choi
  • Contact :
    +82-42-350-2828

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code